The system is indicated for use to necrotise or coagulate soft tissue using interstitial irradiation or thermal therapy under MRI guidance. Credit: Dmitriy Gutarev / Pixabay.

ClearPoint Neuro has enrolled the first participant in a glioblastoma clinical trial of its laser therapy system at Skåne University Hospital in Lund, Sweden.

Sponsored by Clinical Laserthermia Systems (CLS), the Safety and Feasibility of Magnetic Resonance (MR)-guided Laser Thermal Ablation of Brain Lesions study will evaluate the ClearPoint Prism Neuro Laser Therapy System.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The prospective single-centre, single-arm clinical trial has been designed to assess the feasibility and safety of using the minimally invasive MR-guided system for ablating tumours in up to five patients with glioblastoma.

The ClearPoint Prism Neuro Laser Therapy System has been indicated for use to necrotise or coagulate soft tissue using interstitial irradiation or thermal therapy under the guidance of magnetic resonance imaging (MRI) in neurosurgery.

It includes a clinical solution that combines the ClearPoint navigation platform with a thermal ablation monitoring software, known as Thermoguide, from Image Guided Therapy (IGT), which is based in Bordeaux, France.

See Also:

The company holds the exclusive global rights for the commercialisation of the system by CLS for neuro applications.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ClearPoint Neuro president and CEO Joe Burnett said: “We are proud to support SUS Lund and CLS on this pilot study using the innovative laser therapy system to treat glioblastoma lesions.

“The ClearPoint Neuro Navigation System offers an efficient one-room solution that helps neurosurgeons in the United States to accurately place laser fibres and help treat brain tumours, radiation necrosis and epileptic foci in thousands of patients.

“Expanding brain and spine laser therapy treatment options for patients and neurosurgeons in the EU, and beyond, is a key priority in the years ahead.”

CLS will use the data from the glioblastoma clinical trial to seek CE Mark for the system in Europe.